

Oncology Today with Dr Neil Love: Current and Future Management of Follicular Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following molecules is targeted by tazemetostat?
 - CD20
 - EZH2**
 - PI3K
 - POD24
- Which of the following proteins are targeted by the bispecific antibody mosunetuzumab?
 - CD3/CD19
 - CD3/CD20**
 - CD19/CD20
 - CD20/CD38
- The AUGMENT trial evaluated the combination of rituximab and which of the following agents for patients with relapsed/refractory (R/R) follicular lymphoma (FL)?
 - Glofitamab
 - Lenalidomide**
 - Mosunetuzumab
 - Droneksitamab
- Which of the following statements best describes the severity of cytokine release syndrome (CRS) observed with mosunetuzumab in a Phase IB investigation of mosunetuzumab with lenalidomide for R/R FL?
 - CRS was not observed with mosunetuzumab
 - Most events were Grade 1 or 2**
 - Most events were Grade 3 or 4
 - All CRS events led to treatment discontinuation
- Which of the following Grade 1 or 2 adverse events is most commonly observed in patients with FL receiving tazemetostat?
 - Headache
 - Nausea**
 - Thrombocytopenia
 - Tumor lysis syndrome
 - Urinary tract infection